Drug Trial Radar · NCT05985915
A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.
Last checked: Nov 20, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
612
Actual
Start
Oct 27, 2023
Primary completion
Apr 22, 2033
Study completion Apr 22, 2033
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Aug 14, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to measure the long-term safety and tolerability of ianalumab in participants with Sjögren's syndrome who have previously completed treatment from one of two NEPTUNUS 1 year core studies (CVAY736A2301 \[NCT05350072\] or CVAY736A2302 \[NCT05349214\]).
Conditions
- Sjogrens Syndrome
Interventions
Ianalumab (VAY736)Drug
Ianalumab 300 mg / 2 mL, PFS or AI, monthly or every 3 months, solution for injection for subcutaneous use
PlaceboOther
Placebo 0 mg/2 mL PFS or AI, once monthly between doses of Ianalumab 3 monthly , solution for injection for subcutaneous Use
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Treatment-emergent AEs (TEAEs)/SAEsTime frame: Week 52 to Week 464
Locations
198 sites in 35 countries. Site status is shown where the registry gives one.
Providence Medical Foundation
Fullerton, California
Advanced Medical Research
La Palma, California
Medvin Clinical Research
Van Nuys, California
Bay Area Arthritis And Osteoporosis
Brandon, Florida
GNP Research
Cooper City, Florida
Sarasota Arthritis Res Ctr
Sarasota, Florida
West Broward Rheumatology Associates Inc
Tamarac, Florida
Augusta University Georgia
Augusta, Georgia
North GA Rheumatology Group PC
Suwanee, Georgia
Clin Invest Specialists Inc
Orland Park, Illinois
University of Kansas Hospital
Kansas City, Kansas
Ochsner Health System
Baton Rouge, Louisiana
The John Hopkins Jerome L Greene Sjogren
Baltimore, Maryland
Tufts School of Dental Medicine
Boston, Massachusetts
Arthritis Osteoporosis Assoc of NM
Las Cruces, New Mexico
NYU Langone Hospital - Long Island
Mineola, New York
St Lawrence Health System
Potsdam, New York
Arthritis and Osteoporosis
Charlotte, North Carolina
On Site Clinical Solutions Llc
Charlotte, North Carolina
Carolina Arthritis Associates
Wilmington, North Carolina
STAT Research Inc
Dayton, Ohio
RAO Research LLC
Oklahoma City, Oklahoma
Altoona Center for Clin Res
Duncansville, Pennsylvania
West Tennessee Research Institute
Jackson, Tennessee
Shelby Research LLC
Memphis, Tennessee
Precision Comprehensive Research
Colleyville, Texas
Baylor College Of Medicine
Houston, Texas
Prolato Clinical Research Center
Houston, Texas
Houston Rheumatology and Arthrit
Katy, Texas
First Outpatient Research Unit
San Antonio, Texas
Advanced Rheumatology of Houston
The Woodlands, Texas
Arthritis Northwest PLLC
Spokane, Washington
Novartis Investigative Site
Buenos Aires, Argentina
Novartis Investigative Site
Buenos Aires, Argentina
Novartis Investigative Site
CABA, Argentina
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Novartis Investigative Site
Quilmes, Buenos Aires, Argentina
Novartis Investigative Site
San Miguel Tucuman, Tucumán Province, Argentina
Novartis Investigative Site
Maroochydore, Queensland, Australia
Novartis Investigative Site
Woodville South, South Australia, Australia
Showing 40 of 198 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.